Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
These findings follow positive Phase 3 results presented earlier this year
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
The medicine was well tolerated, with no unexpected safety issue
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
More than 40 types of Amyloid proteins are discovered till date
Carson brings with him over two decades of experience in Communications, Public Affairs, and Sustainability
Sarat Kumar has been appointed as CFO of the company and also designated as Key Managerial Personnel with effect from February 21, 2025
Subscribe To Our Newsletter & Stay Updated
